Expression and clinical significance of thymidine kinase 1 and Survivin in thyroid carcinoma and thyroid benign tumor

Objective To investigate the expression of thymidine kinase 1 (TK1) and Survivin in thyroid carcinoma and thyroid benign tumor, and to analyze the clinical significance. Methods The tissue samples of 107 patients with thyroid tumor who underwent surgical resection were collected, including 24 cases of thyroid benign tumor tissues, 83 cases of thyroid carcinoma tissues, and 15 cases of thyroid normal tissues selected as the control group; Immunohistochemical method staining for the paraffin sections(SP method)were used to assess the expression of TK1 and Survivin expression in thyroid carcinoma tissues, thyroid benign tumor tissues and thyroid normal tissues. Results The expression rate of TK1 in thyroid normal tissues, thyroid benign tumor tissues and thyroid carcinoma tissues were 6.67% (1/15), 41.67% (10/24) and 67.47% (56/83) with significant difference (Respectively, t=5.244, 19.301, 5.584, P<0.05), the expressions of TK1 were related thyroid carcinoma to American Joint Committee on Cancer (AJCC) clinical stage, lymph node metastasis and the degree of infiltration (Respectively, t=4.329, 4.506, 4.747, P<0.05); the expression rate of Survivin in thyroid normal tissues, thyroid benign tumor tissues and thyroid carcinoma tissues were 6.67% (1/15), 37.50% (9/24) and 61.45% (51/83) with significant difference (Respectively, t=4.334, 15.306, 4.603, P<0.05), the expressions of Survivin were related thyroid carcinoma to AJCC clinical stage, differentiation degree, lymph node metastasis and the degree of infiltration (Respectively, t=6.295, 8.967, 6.116, 6.005, P<0.05). Conclusion TK1 and Survivin are highly expressed in thyroid carcinoma tissues, TK1 and Survivin are prognostic factor for thyroid carcinoma patients; Detecting the expressive levels of TK1 and Survivin in thyroid carcinoma have certain reference value for judging invasion and metastasis potential of patients of thyroid carcinoma. Key words: Thymidine kinase 1; Survivin; Thyroid carcinoma; Immunohistochemical method